GP IIb/IIIa inhibitors: an evidence-based approach to their use.
D000077284:Abciximab; D000789:Angina, Unstable / Q000188:drug therapy*; D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D019468:Disease Management; D016527:Drug Costs; D000077542:Eptifibatide; D019317:Evidence-Based Medicine; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000191:economics / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000188:drug therapy*; D010455:Peptides / Q000191:economics / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000191:economics / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D000077466:Tirofiban; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D014481:United States
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D014443:Tyrosine; D000077466:Tirofiban; D000077542:Eptifibatide; D000077284:Abciximab